CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.48 Billion CNY | -53.69% |
| 2022 | -964.75 Million CNY | -150.4% |
| 2021 | 1.91 Billion CNY | 634.01% |
| 2020 | -358.49 Million CNY | -134.14% |
| 2019 | -153.1 Million CNY | -10.72% |
| 2018 | -138.28 Million CNY | -114.56% |
| 2017 | -64.45 Million CNY | -29.29% |
| 2016 | -49.85 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -55.27 Million CNY | 67.5% |
| 2024 Q1 | -170.09 Million CNY | 65.82% |
| 2023 Q2 | -701.88 Million CNY | -402.97% |
| 2023 Q1 | -139.54 Million CNY | 67.92% |
| 2023 FY | -1.48 Billion CNY | -53.69% |
| 2023 Q4 | -497.7 Million CNY | -246.59% |
| 2023 Q3 | -143.6 Million CNY | 79.54% |
| 2022 Q3 | -486.64 Million CNY | -345.75% |
| 2022 Q4 | -435.01 Million CNY | 10.61% |
| 2022 Q1 | 121.41 Million CNY | -79.08% |
| 2022 Q2 | -109.17 Million CNY | -189.92% |
| 2022 FY | -964.75 Million CNY | -150.4% |
| 2021 Q4 | 580.49 Million CNY | 46.31% |
| 2021 FY | 1.91 Billion CNY | 634.01% |
| 2021 Q1 | -14.11 Million CNY | 93.61% |
| 2021 Q3 | 396.76 Million CNY | -58.29% |
| 2021 Q2 | 951.24 Million CNY | 6839.74% |
| 2020 Q3 | -71.94 Million CNY | 24.12% |
| 2020 FY | -358.49 Million CNY | -134.14% |
| 2020 Q2 | -94.81 Million CNY | -1223.79% |
| 2020 Q1 | -7.16 Million CNY | 92.97% |
| 2020 Q4 | -220.74 Million CNY | -206.84% |
| 2019 Q3 | -2.99 Million CNY | 87.75% |
| 2019 FY | -153.1 Million CNY | -10.72% |
| 2019 Q2 | -24.44 Million CNY | 45.97% |
| 2019 Q1 | -45.24 Million CNY | -4.26% |
| 2019 Q4 | -101.83 Million CNY | -3300.81% |
| 2018 Q1 | -25.74 Million CNY | 25.54% |
| 2018 Q3 | -43.4 Million CNY | -68.61% |
| 2018 Q4 | -43.4 Million CNY | 0.0% |
| 2018 FY | -138.28 Million CNY | -114.56% |
| 2018 Q2 | -25.74 Million CNY | 0.0% |
| 2017 Q2 | -16.11 Million CNY | 0.0% |
| 2017 Q4 | -34.57 Million CNY | 0.0% |
| 2017 FY | -64.45 Million CNY | -29.29% |
| 2017 Q1 | -16.11 Million CNY | 0.0% |
| 2016 Q1 | -12.46 Million CNY | 0.0% |
| 2016 FY | -49.85 Million CNY | 0.0% |
| 2016 Q4 | -16.11 Million CNY | 0.0% |
| 2016 Q2 | -12.46 Million CNY | 0.0% |
| 2015 Q4 | -12.46 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 1511.601% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 178.869% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | -809.936% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -9555.718% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | -2713.266% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 8979.698% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 638.667% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | -5040.7% |
| PuraPharm Corporation Limited | -106.08 Million HKD | -1297.736% |
| SSY Group Limited | 1.31 Billion HKD | 212.446% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 1236.515% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 655.397% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 138.47% |